SMT202400253T1 - Agenti pan-genotipici contro influenzavirus e metodi per usare gli stessi - Google Patents

Agenti pan-genotipici contro influenzavirus e metodi per usare gli stessi

Info

Publication number
SMT202400253T1
SMT202400253T1 SM20240253T SMT202400253T SMT202400253T1 SM T202400253 T1 SMT202400253 T1 SM T202400253T1 SM 20240253 T SM20240253 T SM 20240253T SM T202400253 T SMT202400253 T SM T202400253T SM T202400253 T1 SMT202400253 T1 SM T202400253T1
Authority
SM
San Marino
Prior art keywords
genotypic
pan
methods
same
influenza virus
Prior art date
Application number
SM20240253T
Other languages
English (en)
Italian (it)
Inventor
Jeffrey S Glenn
Rachel Hagey
Edward Pham
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of SMT202400253T1 publication Critical patent/SMT202400253T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SM20240253T 2016-03-02 2017-03-01 Agenti pan-genotipici contro influenzavirus e metodi per usare gli stessi SMT202400253T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302548P 2016-03-02 2016-03-02
EP20208373.9A EP3800257B1 (en) 2016-03-02 2017-03-01 Pan-genotypic agents against influenza virus and methods of using the same

Publications (1)

Publication Number Publication Date
SMT202400253T1 true SMT202400253T1 (it) 2024-09-16

Family

ID=59743201

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240253T SMT202400253T1 (it) 2016-03-02 2017-03-01 Agenti pan-genotipici contro influenzavirus e metodi per usare gli stessi

Country Status (17)

Country Link
US (1) US10597658B2 (cg-RX-API-DMAC7.html)
EP (3) EP4389221A3 (cg-RX-API-DMAC7.html)
JP (3) JP7536272B2 (cg-RX-API-DMAC7.html)
CN (1) CN108778344A (cg-RX-API-DMAC7.html)
CA (1) CA3014776A1 (cg-RX-API-DMAC7.html)
DK (1) DK3800257T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981765T3 (cg-RX-API-DMAC7.html)
FI (1) FI3800257T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240765T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066977T2 (cg-RX-API-DMAC7.html)
LT (1) LT3800257T (cg-RX-API-DMAC7.html)
PL (1) PL3800257T3 (cg-RX-API-DMAC7.html)
PT (1) PT3800257T (cg-RX-API-DMAC7.html)
RS (1) RS65707B1 (cg-RX-API-DMAC7.html)
SI (1) SI3800257T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400253T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017151795A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
CN115997014A (zh) * 2020-02-14 2023-04-21 小利兰·斯坦福大学董事会 抗呼吸道病毒的泛基因型药剂及其使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501843A (ja) * 1990-08-14 1994-03-03 アイシス・ファーマシューティカルス・インコーポレーテッド アンチセンスオリゴヌクレオチドによるインフルエンザa型ウイルス,アン・アーバh2n2株の阻害
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
CA2603842A1 (en) * 2005-04-08 2006-10-19 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
EP2239328A3 (en) * 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
CN100562342C (zh) * 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
WO2007084359A2 (en) * 2006-01-17 2007-07-26 Oligos Etc., Inc. Compositions and methods for the treatment of influenza infection
AU2007310982A1 (en) * 2006-10-18 2008-04-24 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
US20090042823A1 (en) 2007-08-10 2009-02-12 Mdrna, Inc. Uses of broad spectrum rnai therapeutics against influenza
US20120003156A1 (en) 2008-07-01 2012-01-05 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
SI2607484T1 (sl) 2008-10-27 2016-11-30 Biomarin Technologies B.V. Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
AU2010319314C1 (en) * 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现

Also Published As

Publication number Publication date
EP3423107A1 (en) 2019-01-09
WO2017151795A1 (en) 2017-09-08
HRP20240765T1 (hr) 2024-09-13
JP2019511471A (ja) 2019-04-25
HUE066977T2 (hu) 2024-09-28
PL3800257T3 (pl) 2024-09-16
SI3800257T1 (sl) 2025-04-30
US20190136242A1 (en) 2019-05-09
DK3800257T3 (da) 2024-06-24
JP2025096365A (ja) 2025-06-26
JP7536272B2 (ja) 2024-08-20
LT3800257T (lt) 2024-07-25
ES2981765T3 (es) 2024-10-10
CN108778344A (zh) 2018-11-09
CA3014776A1 (en) 2017-09-08
RS65707B1 (sr) 2024-08-30
EP3800257B1 (en) 2024-05-01
US10597658B2 (en) 2020-03-24
PT3800257T (pt) 2024-06-26
EP4389221A2 (en) 2024-06-26
EP4389221A3 (en) 2024-11-20
FI3800257T3 (fi) 2024-06-19
EP3423107A4 (en) 2020-01-15
EP3800257A1 (en) 2021-04-07
JP2022176378A (ja) 2022-11-25

Similar Documents

Publication Publication Date Title
ZA201900278B (en) Variant adeno-associated viruses and methods of using
ZA201700165B (en) Influenza virus vaccines and uses thereof
IL247870A0 (en) The hemagglutinin antibodies against influenza b virus and methods of use
EP3119883A4 (en) Influenza virus vectors and uses therefor
GB2539350B (en) Amyloid targeting agents and methods of using the same
EP3277819A4 (en) Adeno-associated virus variants and methods of use thereof
IL258259B (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
SG11201610443WA (en) Influenza virus vaccines and uses thereof
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
IL249660B (en) Methods for treating hepatitis b virus and hepatitis d virus infections
IL255259B (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
PL3800257T3 (pl) Środki pan-genotypowe przeciwko wirusowi grypy i sposoby ich zastosowania
IL246643B (en) Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome
EP3334730A4 (en) Pyrrolomycins and methods of using the same
EP3157950A4 (en) Influenza vaccines and methods of use thereof
SG11201803115TA (en) Brace member and method of assembling the same
ZA201803649B (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
HK40017878A (en) Multibiotic agents and methods of using the same
IL249705A0 (en) Influenza virus vaccines and their uses
IL249704A0 (en) Influenza virus vaccines and their uses
TWI560711B (en) Fastening device and method of using the same
HK1236965A1 (en) Influenza virus vaccines and uses thereof
GB201520019D0 (en) The genome and self-evolution of AI
HK1236968A1 (en) Influenza vaccines and methods of use thereof
TH1501007823A (th) วิธีการเเละองค์ประกอบสำหรับวัคซีนเดงกีไวรัส